Latest Mergers And Acquisitions News

Cann Group Limited delivered record production and revenue growth in Q4 FY2025, securing new funding and advancing a major debt restructuring to set the stage for profitability in FY2026.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.

Tempest Minerals reports a maiden inferred mineral resource of 63.5 million tonnes at 30.6% iron for its Remorse Deposit, alongside promising gold anomalies at its Sanity Target and a successful $1.87 million capital raise.

Delorean Corporation has marked significant progress in Q4 FY2025, advancing its renewable gas infrastructure and securing crucial regulatory support that could unlock new revenue streams.

EQ Resources delivered a robust Q4 FY2025 with strong tungsten output from its Spanish and Australian operations, bolstered by strategic capital raises and key plant enhancements.

Freehill Mining reported a transitional quarter marked by a dip in sales due to project cycles but offset by strategic site acquisitions and a successful capital raise. The company is poised for growth with new processing sites and promising magnetite test results.

Auric Mining wraps up its final gold processing campaign at Jeffreys Find with strong cash flow, while advancing mining and acquisitions at Munda and Higginsville to fuel growth.

Ramelius Resources has completed its acquisition of Spartan Resources, issuing new shares and cash to Spartan shareholders and reshaping its board as it integrates the Dalgaranga asset.

Ramelius Resources has finalized its acquisition of Spartan Resources, issuing new shares and cash to Spartan shareholders while expanding its board and asset portfolio. This move aims to accelerate Ramelius' growth toward becoming a half-million ounce gold producer within five years.

Carbonxt Group Limited advances its Kentucky activated carbon facility with increased ownership and imminent kiln commissioning, while securing $1 million in convertible notes to support growth. The company reports steady revenue and strong market positioning amid tightening US EPA PFAS regulations.

Cambium Bio has cleared key regulatory hurdles for its lead dry eye disease treatment, Elate Ocular, and strengthened its balance sheet with a $2.12 million placement to support upcoming Phase 3 trials.

DigitalX Limited reported a 32.8% increase in digital asset holdings to $72.9 million and raised $20.7 million to pivot its treasury strategy firmly towards Bitcoin. The DigitalX Bitcoin ETF (BTXX) also surged, nearing $53 million in assets under management.